Myriad Genetics (MYGN) 10-Q 2005 Q1 Quarterly report

Use these links to rapidly review the document
MYRIAD GENETICS, INC. INDEX TO FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2004
OR
o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                             to

Commission file number: 0-26642

MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	87-0494517
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
320 Wakara Way, Salt Lake City, UT	84108
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code:(801) 584-3600

        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

        Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes ý    No o

        As of November 1, 2004 the registrant had 30,662,621 shares of $0.01 par value common stock outstanding.

MYRIAD GENETICS, INC.

INDEX TO FORM 10-Q

PART I—Financial Information
Item 1.	Financial Statements:
	Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2004 and June 30, 2004
	Condensed Consolidated Statements of Operations (Unaudited) for the three months ended September 30, 2004 and 2003
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended September 30, 2004 and 2003
	Notes to Condensed Consolidated Financial Statements (Unaudited)
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3.	Quantitative and Qualitative Disclosures About Market Risk
Item 4.	Controls and Procedures
PART II—Other Information
Item 1.	Legal Proceedings
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.	Defaults Upon Senior Securities
Item 4.	Submission of Matters to a Vote of Security Holders
Item 5.	Other Information
Item 6.	Exhibits
Signatures

2

MYRIAD GENETICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

			Sep. 30, 2004			June 30, 2004
			(in thousands, except per share amounts)
Assets
Current assets:
	Cash and cash equivalents		$	65,494		$	83,983
	Marketable investment securities			26,002			31,383
	Prepaid expenses			5,804			7,279
	Trade accounts receivable, less allowance for doubtful accounts of $1,225 at Sep. 30, 2004 and $1,205 at June 30, 2004			16,627			13,994
	Other receivables			1,452			554
		Total current assets		115,379			137,193
Equipment and leasehold improvements:
	Equipment			34,702			34,212
	Leasehold improvements			7,736			7,692
				42,438			41,904
	Less accumulated depreciation and amortization			25,645			24,565
		Net equipment and leasehold improvements		16,793			17,339
Long-term marketable investment securities				38,093			26,473
Other assets				7,213			7,351
			$	177,478		$	188,356
Liabilities and Stockholders' Equity
Current liabilities:
	Accounts payable		$	6,601		$	7,938
	Accrued liabilities			6,103			5,933
	Deferred revenue			1,157			1,209
		Total current liabilities		13,861			15,080
Stockholders' equity:
	Preferred stock, $0.01 par value, 5,000 shares authorized, no shares issued and outstanding			—			—
	Common stock, $0.01 par value, 60,000 shares authorized; issued and outstanding 30,662 at Sep. 30, 2004 and 30,623 at June 30, 2004			307			306
	Additional paid-in capital			312,684			312,453
	Accumulated other comprehensive loss			(111	)		(212	)
	Accumulated deficit			(149,263	)		(139,271	)
		Total stockholders' equity		163,617			173,276
			$	177,478		$	188,356

See accompanying notes to condensed consolidated financial statements (Unaudited).

3

MYRIAD GENETICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

				Three Months Ended
				Sep. 30, 2004			Sep. 30, 2003
				(in thousands, except per share amounts)
Revenues:
	Predictive medicine revenue			$	14,429		$	8,064
	Research revenue				2,281			5,079
	Related party research revenue				—			529
		Total research revenue			2,281			5,608
			Total revenues		16,710			13,672
Costs and expenses:
	Predictive medicine cost of revenue				4,239			2,758
	Research and development expense				13,132			12,974
	Selling, general and administrative expense				9,956			8,108
			Total costs and expenses		27,327			23,840
			Operating loss		(10,617	)		(10,168	)
Other income (expense):
	Interest income				632			569
	Other				(7	)		(10	)
					625			559
			Net loss	$	(9,992	)	$	(9,609	)
Basic and diluted loss per share				$	(0.33	)	$	(0.35	)
Basic and diluted weighted average shares outstanding					30,649			27,087

See accompanying notes to condensed consolidated financial statements (Unaudited).

4

MYRIAD GENETICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

					Three Months Ended
					Sep. 30, 2004			Sep. 30, 2003
					(In thousands)
Cash flows from operating activities:
	Net loss				$	(9,992	)	$	(9,609	)
	Adjustments to reconcile net loss to net cash used in operating activities:
		Depreciation and amortization				1,486			1,419
		Loss on disposition of assets				7			10
		Bad debt expense				209			148
		Changes in operating assets:
			Trade receivables			(2,842	)		396
			Other receivables			(898	)		1,013
			Related party receivables			—			(26	)
			Prepaid expenses			1,475			101
			Accounts payable			(1,337	)		(5,645	)
			Accrued liabilities			170			(899	)
			Deferred revenue			(52	)		(583	)
				Net cash used in operating activities		(11,774	)		(13,675	)
Cash flows from investing activities:
	Capital expenditures					(809	)		(1,443	)
	Purchases of marketable investment securities					(20,512	)		(14,161	)
	Proceeds from sales and maturities of marketable investment securities					14,374			15,869
				Net cash (used in) provided by investing activities		(6,947	)		265
Cash flows from financing activities:
	Net proceeds from issuance of common stock					232			40
				Net cash provided by financing activities		232			40
Net decrease in cash and cash equivalents						(18,489	)		(13,370	)
Cash and cash equivalents at beginning of period						83,983			61,603
Cash and cash equivalents at end of period					$	65,494		$	48,233

See accompanying notes to condensed consolidated financial statements (Unaudited).

5

MYRIAD GENETICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(1)   Basis of Presentation

        The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the "Company") in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with accounting principles generally accepted in the United States. The unaudited condensed consolidated financial statements herein should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2004, included in the Company's Annual Report on Form 10-K for the year ended June 30, 2004. Operating results for the three month period ended September 30, 2004 may not necessarily be indicative of the results to be expected for any other interim period or for the full year.

        The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(2)   Stock-Based Compensation

        In 2003 the Company adopted the 2003 Employee, Director and Consultant Stock Option Plan, which, together with our earlier stock option plan, are accounted for under the recognition and measurement principles of APB Opinion No. 25,Accounting for Stock Issued to Employees, and related Interpretations. No stock-based employee compensation cost is reflected in net loss, as all options granted under these plans have an exercise price equal to the market value of the underlying common stock on the date of grant and no modifications have been made to any of the awards. The following table illustrates the effect on net loss and loss per share if the Company had applied the fair value recognition provisions of SFAS No. 123,Accounting for Stock-Based Compensation, to stock-based employee compensation.

	Three Months Ended Sep. 30,
	2004			2003
	(in thousands, except per share amounts)
Net loss, as reported	$	(9,992	)	$	(9,609	)
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of tax related effects		(6,416	)		(6,529	)
Pro forma net loss	$	(16,408	)	$	(16,138	)
Loss per share:
Basic and diluted—as reported	$	(0.33	)	$	(0.35	)
Basic and diluted—pro forma	$	(0.54	)	$	(0.60	)

6

(3)   Comprehensive Loss

        The components of the Company's comprehensive loss are as follows (in thousands):

	Three Months Ended Sep. 30,
	2004			2003
Net loss	$	(9,992	)	$	(9,609	)
Unrealized gain (loss) on available-for-sale securities		101			(151	)
Comprehensive loss	$	(9,891	)	$	(9,760	)

(4)   Net Loss Per Common Share

        Loss per common share is computed based on the weighted-average number of common shares and, as appropriate, dilutive potential common shares outstanding during the period. Stock options and warrants are considered to be potential common shares.

        Basic loss per common share is the amount of loss for the period available to each share of common stock outstanding during the reporting period. Diluted loss per share is the amount of loss for the period available to each share of common stock outstanding during the reporting period and to each share that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares outstanding during the period.

        In calculating loss per common share the net loss and the weighted average common shares outstanding were the same for both the basic and diluted calculation.

        As of September 30, 2004 and 2003, there were antidilutive potential common shares of 6,630,433 and 5,507,614, respectively. Accordingly, these potential common shares were not included in the computation of diluted loss per share for the periods presented, but may be dilutive to future basic and diluted earnings per share.

(5)   Segment and Related Information

        The Company's business units have been aggregated into three reportable segments: (i) research, (ii) predictive medicine, and (iii) drug development. The research segment is focused on the discovery of genes and protein pathways related to major common diseases. The predictive medicine segment provides testing to determine predisposition to common diseases. The drug development segment is focused on the development of therapeutic products for the treatment and prevention of major diseases.

7

        The accounting policies of the segments are the same as those described in the basis of presentation (note 1). The Company evaluates segment performance based on results from operations before interest income and expense and other income and expense.

		Research			Predictive medicine			Drug development			Total
		(in thousands)
Three months ended Sep. 30, 2004:
	Revenues	$	2,281		$	14,429		$	—		$	16,710
	Depreciation and amortization		553			475			458			1,486
	Segment operating gain (loss)		(3,474	)		1,997			(9,140	)		(10,617	)
Three months ended Sep. 30, 2003:
	Revenues		5,608			8,064			—			13,672
	Depreciation and amortization		578			427			414			1,419
	Segment operating gain (loss)		(2,587	)		(1,027	)		(6,554	)		(10,168	)

	Three Months Ended Sep. 30,
	2004			2003
	(in thousands)
Total operating loss for reportable segments	$	(10,617	)	$	(10,168	)
Interest income		632			569
Other		(7	)		(10	)
Net loss	$	(9,992	)	$	(9,609	)

8

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

        We are a leading biopharmaceutical company focused on the development and marketing of novel therapeutic and molecular diagnostic products. We employ a number of proprietary technologies that permit us to understand the genetic basis of human disease and the role that genes and their related proteins play in the onset and progression of disease. We use this information to guide the development of new healthcare products that treat major diseases and assess a person's risk of disease later in life.

        We believe that the future of medicine lies in the creation of new classes of drugs that treat the underlying cause, not just the symptoms, of disease and that may be useful in disease prevention. By understanding the genetic basis of disease, we believe we will be able to develop drugs that are safer and more efficacious. In addition, we believe that advances in the emerging field of predictive medicine will improve our ability to determine which patients are subject to a greater risk of developing these diseases and who therefore would benefit from these new preventive therapies.

        Myriad researchers have made important discoveries in the fields of cancer, Alzheimer's disease, and infectious diseases such as AIDS. These discoveries point to novel disease pathways that may pave the way for the development of new classes of drugs. Flurizan™, our lead therapeutic candidate for the treatment of Alzheimer's disease, recently completed a phase 1 human clinical trial which evaluated the safety of Flurizan™ in the elderly population. The study found that Flurizan™ appeared to be safe and well tolerated in the healthy older volunteers. We are currently conducting a phase 2 human clinical study in Europe and Canada to assess the efficacy of Flurizan™ for the treatment of patients with mild to moderate Alzheimer's disease. Flurizan™ is also in a large, multi-center phase²/3 human clinical trial in the U.S. for the treatment of patients with pre-metastatic prostate cancer. We intend to independently develop and, subject to regulatory approval, market our therapeutic products, particularly in the area of cancer, viral disease, and Alzheimer's disease.

        We also have a number of drug candidates in late-stage preclinical development in the areas of cancer, emesis, and AIDS. MPI-176716 was developed by our researchers based on the discovery of a novel drug target for the induction of programmed cell death, or apoptosis. This drug candidate causes tumor remission in animal models and appears to be synergistic with both the taxane and platin classes of chemotherapeutic drugs. MPC-6827 is also a broad apoptosis-inducing cancer drug candidate that has shown strong activity against cancers of the ovary, breast, prostate, pancreas and skin (melanoma). These cancer drug candidates are expected to enter human clinical testing this year.

        As published in the scientific journalCell, our scientists and their collaborators discovered the viral budding mechanism in HIV and other viruses. This discovery led to the development of MPI-49839, a viral budding inhibitor and new class of drugs for the treatment of AIDS. MPI-49839 has demonstrated strong anti-HIV activity and has been shown to be effective against many of the drug resistant strains of HIV. MPI-49839 is in late-stage preclinical formulation in preparation of human clinical testing in the near future.

        We also have developed and commercialized a number of innovative predictive medicine products, including BRACAnalysis®, which assesses a woman's risk of developing breast and ovarian cancer, COLARIS® and COLARIS AP®, which determine a person's risk of developing colon cancer, and MELARIS®, which assesses a person's risk of developing malignant melanoma, a deadly form of skin cancer. In the United States we market these products using our own 100 person sales force. Predictive medicine revenues were $14.4 million for the three months ended September 30, 2004.

        We have devoted substantially all of our resources to undertaking our drug discovery and development programs, operating our predictive medicine business, and continuing our research and development efforts. Our revenues have consisted primarily of sales of predictive medicine products

9

and research payments. We have yet to attain profitability and, for three months ended September 30, 2004, we had a net loss of $10.0 million. As of September 30, 2004 we had an accumulated deficit of $149.3 million.

        We expect to incur losses for at least the next several years, primarily due to the expansion of our drug discovery and development efforts, the initiation and continuing conduct of human clinical trials, the launch of new predictive medicine products, the continuation of our internal research and development programs, and expansion of our facilities. Additionally, we expect to incur substantial sales, marketing and other expenses in connection with building our pharmaceutical and predictive medicine businesses. We expect that losses will fluctuate from quarter to quarter and that such fluctuations may be substantial.

Critical Accounting Policies

        Critical accounting policies are those policies which are both important to the portrayal of a company's financial condition and results and require management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies are as follows:

•

revenue recognition;



•

allowance for doubtful accounts; and



•

investments in privately-held companies.

        Revenue Recognition.    Research revenues include revenues from research agreements, milestone payments, and technology licensing agreements. In applying the principles of SAB 104 to research and technology license agreements we consider the terms and conditions of each agreement separately to arrive at a proportional performance methodology of recognizing revenue. Such methodologies involve recognizing revenue on a straight-line basis over the term of the agreement and based on costs incurred relative to the total estimated contract costs (cost-to-cost method). We make adjustments, if necessary, to the estimates used in our cost-to-cost calculations as work progresses and we gain experience.    The principal costs under these agreements are for personnel expenses to conduct research and development but also include costs for materials and other direct and indirect items necessary to complete the research under these agreements. Actual results may vary from our estimates. Payments received on uncompleted long-term contracts may be greater than or less than incurred costs and estimated earnings and have been recorded as other receivables or deferred revenues in the accompanying consolidated balance sheets. We recognize revenue from milestone payments as agreed-upon events representing the achievement of substantive steps in the development process are achieved and where the amount of the milestone payments approximates the value of achieving the milestone. We recognize revenue from up-front nonrefundable license fees on a straight-line basis over the period of our continued involvement in the research and development project.

        Predictive medicine revenues include revenues from the sale of predictive medicine products and related marketing agreements. Predictive medicine revenue is recognized upon completion of the test and communication of results. Up-front payments related to marketing agreements are recognized ratably over the life of the agreement.

        Allowance for Doubtful Accounts.    The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amount of assets at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Trade accounts receivable are comprised of amounts due from sales of our predictive medicine products. We analyze trade accounts receivable and consider historic experience, customer creditworthiness, facts and circumstances specific to outstanding balances, and payment term changes when evaluating the

10

adequacy of the allowance for doubtful accounts. Changes in these factors could result in material adjustments to the expense recognized for bad debt.

        Investments in Privately-Held Companies.    We review the valuation of our investments in privately-held biotechnology and pharmaceutical companies for possible impairment as changes in facts and circumstances indicate that impairment should be assessed. The amount of impairment, if any, and valuation of these investments are based on our estimates and, in certain circumstances, the completion of independent, third-party appraisals of the investments. Inherent in these estimates and appraisals are assumptions such as the comparability of the investee to similar publicly traded companies, the value of the investee's underlying research and development efforts, the likelihood that the investee's current research projects will result in a marketable product, and the investee's expected future cash flows. Accordingly, the amount recognized by us upon ultimate liquidation of these investments may vary significantly from the estimated fair values at September 30, 2004.

Results of Operations for the Three Months Ended September 30, 2004 and 2003

        Predictive medicine revenues for the three months ended September 30, 2004 were $14.4 million compared to $8.1 million for the same three months in 2003, an increase of 79%. Predictive medicine revenue is comprised primarily of sales of predictive medicine products, and also includes some marketing fees and forensic DNA analysis fees. Increased sales, marketing, and education efforts, coupled with recent publications concerning the clinical utility of our products have resulted in wider acceptance of our products by the medical community and increased revenues for the three months ended September 30, 2004. There can be no assurance that predictive medicine revenues will continue to increase at historical rates.

        Research revenues for the three months ended September 30, 2004 were $2.3 million compared to $5.6 million for the same three months in 2003. Related party research revenues included in total research revenues for the three months ended September 30, 2004 and 2003 were $0 and $0.5 million, respectively. Related party research revenue is comprised of certain research services performed for Prolexys Pharmaceuticals, Inc., which is 49% owned by us. The agreement to provide these research services was terminated effective January 26, 2004. This 59% decrease in total research revenue is primarily attributable to the successful completion of one of our research collaborations with a corporate partner. Current levels of research revenues reflect our continued focus on internal drug development programs and de-emphasis of external research collaborations. Research revenue from our research collaboration agreements is recognized using a proportional performance methodology. Consequently, as these programs progress and costs increase or decrease, revenues may increase or decrease proportionately.

        Predictive medicine cost of revenue for the three months ended September 30, 2004 was $4.2 million compared to $2.8 million for the same three months in 2003. This increase of 54% in predictive medicine cost of revenue is primarily due to the 79% increase in predictive medicine revenues for the three months ended September 30, 2004 compared to the same three months in 2003. This increase was partially offset by technology improvements and efficiency gains in the operation of our predictive medicine business. Our technology and efficiency improvements also contributed to an increase in our gross profit margin, which was 71% for the three months ended September 30, 2004 compared to 66% for the same three months in 2003. There can be no assurance that predictive medicine gross profit margins will continue to increase at historical rates.

        Research and development expenses for the three months ended September 30, 2004 were $13.1 million compared to $13.0 million for the same three months in 2003. This increase of 1% was primarily due to increased costs associated with our ongoing clinical trials in Alzheimer's disease and prostate cancer, increases in our other drug discovery and drug development programs. These increases added approximately $3.5 million to our research and development expenses for the three months

11

ended September 30, 2004 compared to the same three months in 2003. These increases were partially offset by the completion of one of our research collaborations, which resulted in decreased research and development expenses of approximately $3.4 million for the three months ended September 30, 2004 compared to the same three months in 2003. We expect our research and development expenses to continue to fluctuate based on changes in our research programs and the progression of our drug development programs.

        Selling, general and administrative expenses for the three months ended September 30, 2004 were $10.0 million compared to $8.1 million for the same three months in 2003. Selling, general and administrative expenses consist primarily of salaries, commissions and related personnel costs for sales, marketing, executive, legal, finance, accounting, human resources, business development, allocated facilities expenses and other corporate expenses. This increase of 23% was primarily attributable to increased sales and marketing commissions and expenses incurred to support growth in our predictive medicine business, which resulted in an increase of approximately $1.4 million to our selling, general, and administrative expense for the three months ended September 30, 2004 compared to the same three months in 2003. In addition, general corporate expenses in support of our therapeutic product development efforts resulted in an increase of approximately $0.5 million to our selling, general, and administrative expense for the three months ended September 30, 2004 compared to the same three months in 2003. We expect our selling, general and administrative expenses will continue to fluctuate depending on the number and scope of new product launches and our drug discovery and drug development efforts.

Liquidity and Capital Resources

        Cash, cash equivalents, and marketable investment securities decreased $12.3 million or 9% from $141.8 million at June 30, 2004 to $129.6 million at September 30, 2004. This decrease in cash, cash equivalents, and marketable investment securities is primarily attributable to increased expenditures for our ongoing clinical trials, internal drug development programs and other expenditures incurred in the ordinary course of business. As a result of changes in interest rates and cash, cash equivalents, and marketable investment securities, interest income for the three months ended September 30, 2004 was $0.63 million compared to $0.57 million for the same three months in 2003, an increase of 11%.

        Net cash used in operating activities was $11.8 million during the three months ended September 30, 2004 compared to $13.7 million used in operating activities during the same three months in 2003. Trade receivables increased $2.8 million between June 30, 2004 and September 30, 2004, primarily due to increases in predictive medicine sales during the same period. Prepaid expenses decreased by $1.5 million between June 30, 2004 and September 30, 2004, primarily due to the usage of lab supplies previously purchased at a discount. Accounts payable decreased by $1.3 million between June 30, 2004 and September 30, 2004, primarily as a result of payments made for purchases of equipment and lab supplies.

        Our investing activities used cash of $6.9 million during the three months ended September 30, 2004 and provided cash of $0.3 million during the same three months in 2003. Investing activities were comprised primarily of changes to marketable investment securities and capital expenditures for research equipment.

        We believe that with our existing capital resources, we will have adequate funds to maintain our current and planned operations for at least the next two years, although no assurance can be given that changes will not occur that would consume available capital resources before such time. Our future capital requirements, cash flows, and results of operations could be affected by and will depend on many factors, including:

•

the progress of our preclinical and clinical activities;

12

•

the progress of our research and development programs;



•

the progress of our drug discovery and drug development programs;



•

the cost of developing and launching additional predictive medicine products;



•

the costs of filing, prosecuting and enforcing patent claims;



•

the costs associated with competing technological and market developments;



•

the costs associated with potential litigation;



•

the payments received under collaborative agreements and changes in collaborative research relationships;



•

the costs associated with potential commercialization of our discoveries, if any, including the development of manufacturing, marketing and sales capabilities; and



•

the cost and availability of third-party financing for capital expenditures and administrative and legal expenses.

        On November 9, 2001, we filed a shelf registration statement on Form S-3 (Registration No. 333-73124) with the Securities and Exchange Commission for the sale of up to $250 million of various types of securities. We currently have approximately $139.7 million of these securities available for sale at our discretion upon filing of a prospectus supplement with the SEC. Because of our significant long-term capital requirements, we intend to raise funds when conditions are favorable, even if we do not have an immediate need for additional capital at such time.

Effects of Inflation

        We do not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

        We maintain an investment portfolio in accordance with our Investment Policy. The primary objectives of our Investment Policy are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. Our Investment Policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment.

        Our investments consist of securities of various types and maturities of three years or less, with a maximum average maturity of 12 months. These securities are classified as available-for-sale, which are recorded on the balance sheet at fair market value with unrealized gains or losses reported as part of accumulated other comprehensive income. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. A decline in the market value of any marketable investment security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security.

        The securities held in our investment portfolio are subject to interest rate risk. Changes in interest rates affect the fair market value of the marketable investment securities. After a review of our marketable securities as of September 30, 2004, we have determined that in the event of a hypothetical ten percent increase in interest rates, the resulting decrease in fair market value of our marketable investment securities would be insignificant to the consolidated financial statements as a whole.

Item 4. Controls and Procedures

(a)

Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as

13

defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were adequate and effective to ensure that material information relating to us, including our consolidated subsidiaries, was made known to them by others within those entities, particularly during the period in which this Quarterly Report on Form 10-Q was being prepared.

In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

(b)

Changes in Internal Controls. There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Certain Factors That May Affect Future Results of Operations

        The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. This Quarterly Report contains such "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

        Words such as "may," "anticipate," "estimate," "expects," "projects," "intends," "plans," "believes" and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among other things: our inability to further identify, develop and achieve commercial success for new products and technologies; our ability to discover drugs that are safer and more efficacious; our ability to develop predictive medicine products that help determine which patients are subject to greater risk of developing diseases and who would therefore benefit from new preventive therapies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates; our dependence upon pharmaceutical and biotechnology collaborations; the levels and timing of payments under our collaborative agreements; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; our ability to protect our proprietary technologies; patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended June 30, 2004, which has been filed with the Securities and Exchange Commission.

        In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only of the date of this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

14

PART II—Other Information

Item 1. Legal Proceedings.

        Neither the Company nor any of its subsidiaries is a party to any material legal proceedings.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

        None.

Item 3. Defaults Upon Senior Securities.

        None.

Item 4. Submission of Matters to a Vote of Security Holders.

        None.

Item 5. Other Information.

        None.

Item 6. Exhibits.

(a)

Exhibits

31.1

Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

32.1

Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b)

Reports on Form 8-K

        On August 18, 2004, we furnished a Current Report on Form 8-K to disclose that we had publicly disseminated a press release announcing our financial results for the three and twelve months ended June 30, 2004.

15

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MYRIAD GENETICS, INC.
Date: November 9, 2004	By:	/s/  PETER D. MELDRUM      Peter D. Meldrum President and Chief Executive Officer
Date: November 9, 2004	By:	/s/  JAY M. MOYES      Jay M. Moyes Vice President of Finance Principal financial and chief accounting officer

16